EcoDrugPlus

Janus Kinase 1

Ensembl ID : ENSTNIG00000018107
Gene Symbol: JAK1
2 Cross references
212 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSTNIG00000004943
Gene Symbol: JAK2A
2 Cross references
199 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSTNIG00000015572
Gene Symbol: JAK2B
2 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSTNIG00000004103
Gene Symbol: KITB
2 Cross references
200 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTNIG00000017609
Gene Symbol: LYN
2 Cross references
195 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSTNIG00000015577
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSTNIG00000007288
Gene Symbol: MAPKAPK2
2 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSTNIG00000016693
Gene Symbol: MAPKAPK5
2 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSTNIG00000010166
Gene Symbol: MKNK2B
2 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSTNIG00000006171
Gene Symbol: MCL1B
2 Cross references
211 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSTNIG00000016058
Gene Symbol: MET
2 Cross references
205 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSTNIG00000012906
Gene Symbol: MLST8
2 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).